Dyax Corp. to Participate in the Needham Healthcare Conference

  Dyax Corp. to Participate in the Needham Healthcare Conference

Needham Healthcare Conference 2013

Business Wire

BURLINGTON, Mass. -- April 29, 2013

Dyax Corp. (NASDAQ: DYAX) announced today that the Company will participate in
the Needham Healthcare Conference, being held April 30-May 1, 2013, at the
Westin New York Grand Central Hotel in New York City. Gustav Christensen,
President and Chief Executive Officer of Dyax, will present on Tuesday, April
30 at 10:40 AM (ET). Mr. Christensen will provide a corporate update regarding
the Company’s key value drivers – KALBITOR^® (ecallantide) and the angioedema
portfolio, as well as the Licensing and Funded Research Program (LFRP).

This presentation will be webcast live and may be accessed by visiting the
Investor Relations section of the company website at www.dyax.com. The webcast
will also be available on the Dyax website for a limited period of time
following the conferences.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the discovery,
development and commercialization of novel biotherapeutics for unmet medical
needs. The Company’s key value drivers are the KALBITOR®(ecallantide)
business and the angioedema portfolio, as well as the Licensing and Funded
Research Program (LFRP).

Dyax developed KALBITOR on its own and, since February 2010, has been selling
it in the United States for the treatment of acute attacks of hereditary
angioedema (HAE) in patients 16 years of age and older. Outside the United
States, the Company has established partnerships to obtain regulatory approval
for and commercialization of KALBITOR in certain markets and is evaluating
opportunities in others.

The Company is currently developing products to expand its angioedema
portfolio, includinga suite of diagnosticassaysto identify
plasma-kallikrein-(bradykinin)-mediated (PKM) angioedemasand a therapeutic
candidate, DX-2930, for the prophylactic treatment ofHAE andPKM angioedemas.

KALBITOR and DX-2930 were identified using Dyax’s patented phage display
technology, which rapidly selects compounds that bind with high affinity and
specificity to therapeutic targets. Dyax leverages this technology broadly
through the LFRP. This program has provided the Company a portfolio of product
candidates being developed by its licensees, which currently
includes13royalty and/or milestoneeligibleproduct candidates in various
stages of clinical development, including three in Phase 3 trials.

For additional information about Dyax, please visitwww.dyax.com.

Foradditionalinformation about KALBITOR, including full prescribing
information and boxed warning on serious hypersensitivity
reactions,pleasevisitwww.KALBITOR.com.

Disclaimer

This press release contains forward-looking statements. Statements that are
not historical facts are based onDyax'scurrent expectations, beliefs,
assumptions, estimates, forecasts and projections about the industry and
markets in whichDyaxcompetes. The statements contained in this release are
not guarantees of future performance and involve certain risks, uncertainties
and assumptions, which are difficult to predict. Therefore, actual outcomes
and results may differ materially from what is expressed in such
forward-looking statements. Important factors which may affect future
performance include the risks that: DX-2930 may not show sufficient
therapeutic effect or an acceptable safety profile in clinical trials or could
take longer to gain regulatory approval thanDyaxexpects or may never gain
approval; others may develop products superior to KALBITOR or DX-2930;
KALBITOR and/or DX-2930 may not gain market acceptance;Dyaxis dependent on
the expertise, effort, priorities and contractual obligations of third parties
in the manufacture, marketing, sales and distribution of KALBITOR and DX-2930;
and other risk factors described or referred to in Item 1A, "Risk Factors"
inDyax'smost recent Annual Report on Form 10-K and other periodic reports
filed with theSecurities and Exchange Commission.Dyaxcautions investors not
to place undue reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this release,
andDyaxundertakes no obligations to update or revise these statements,
except as may be required by law.

Dyax, theDyaxlogo and KALBITOR are registered marks ofDyax Corp.

Contact:

Dyax Corp.
Jennifer Robinson, 617-250-5741
Associate Director, Investor Relations and
Corporate Communications
jrobinson@dyax.com
 
Press spacebar to pause and continue. Press esc to stop.